Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study
Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, Hehlmann R, Heim D, Krause S, Le Coutre P, Niederwieser D, Mayer J, Lange T, Haenel M, Stegelmann F, Gil A, Ernst T, Fabisch C, Pfirrmann M (2018)
Publication Type: Conference contribution
Publication year: 2018
Journal
Publisher: AMER SOC HEMATOLOGY
City/Town: WASHINGTON
Conference Proceedings Title: BLOOD
Event location: San Diego, CA
DOI: 10.1182/blood-2018-99-112119
Authors with CRIS profile
Involved external institutions
Masaryk University
Czech Republic (CZ)
Universität Bern
Switzerland (CH)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Klinikum Chemnitz
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
ELN Foundation
Germany (DE)
Asklepios Klinik Weissenfels
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Schwarzwald-Baar Klinikum
Germany (DE)
Universitätsspital Basel
Switzerland (CH)
Universitätsklinikum Mannheim
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Czech Republic (CZ)
Universität Bern
Switzerland (CH)
Universitätsklinikum Jena
Germany (DE)
Universitätsklinikum Leipzig
Germany (DE)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Philipps-Universität Marburg
Germany (DE)
Klinikum Chemnitz
Germany (DE)
Ludwig-Maximilians-Universität (LMU)
Germany (DE)
ELN Foundation
Germany (DE)
Asklepios Klinik Weissenfels
Germany (DE)
Universitätsklinikum Ulm
Germany (DE)
Schwarzwald-Baar Klinikum
Germany (DE)
Universitätsspital Basel
Switzerland (CH)
Universitätsklinikum Mannheim
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
How to cite
APA:
Hochhaus, A., Saussele, S., Baerlocher, G.M., Bruemmendorf, T.H., Burchert, A., La Rosee, P.,... Pfirrmann, M. (2018). Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study. In BLOOD. San Diego, CA, US: WASHINGTON: AMER SOC HEMATOLOGY.
MLA:
Hochhaus, Andreas, et al. "Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study." Proceedings of the 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA WASHINGTON: AMER SOC HEMATOLOGY, 2018.
BibTeX: Download